New Risk • May 31
New major risk - Revenue and earnings growth Revenue has declined by 6.2% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 6.2% over the past year. Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.2b market cap, or US$34.6m). 공고 • Apr 21
Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces an Equity Buyback for KRW 1,000 million worth of its shares. Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,000 worth of its shares pursuant to a contract with SHINYOUNG SECURITIES CO.,LTD. The purpose of the share repurchase is stock price stability and enhance in shareholder value. The repurchase program will expire on October 21, 2026. As of April 19, 2026, the company had 0 shares within scope available for dividend and had 103,532 shares in treasury through other repurchase. New Risk • Apr 03
New major risk - Dividend sustainability The dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 93% Dividend yield: 3.8% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Dividend is not well covered by earnings and cash flows. Payout ratio: 0% Cash payout ratio: 93% Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩54.8b market cap, or US$36.4m). 공고 • Mar 17
Cellromax Science Co., Ltd., Annual General Meeting, Mar 31, 2026 Cellromax Science Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: auditorium, 357, guseong-ro, giheung-gu, gyeonggi-do, yongin South Korea Declared Dividend • Dec 18
Dividend of ₩50.00 announced Shareholders will receive a dividend of ₩50.00. Ex-date: 29th December 2025 Payment date: 1st January 1970 Dividend yield will be 2.9%, which is lower than the industry average of 3.7%. New Risk • Dec 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.8% average weekly change). Market cap is less than US$100m (₩79.0b market cap, or US$54.0m). 공고 • Sep 25
Cellromax Science Co., Ltd. (KOSDAQ:A471820) agreed to acquire 17.17% stake in SNBioScience Inc. from OCI Holdings Company Ltd. (KOSE:A010060) for KRW 6 billion. Cellromax Science Co., Ltd. (KOSDAQ:A471820) agreed to acquire 17.17% stake in SNBioScience Inc. from OCI Holdings Company Ltd. (KOSE:A010060) for KRW 6 billion on September 23, 2025. A cash consideration of KRW 6 billion will be paid by Cellromax Science for 1.049609 million shares. The transaction will be financed through cash on hand available.
The expected completion of the transaction is September 30, 2025. New Risk • Aug 01
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Market cap is less than US$100m (₩66.9b market cap, or US$47.7m). 공고 • Jul 10
Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces an Equity Buyback for KRW 1,500 million worth of its shares. Cellromax Science Co., Ltd. (KOSDAQ:A471820) announces a share repurchase program. Under the program, the company will repurchase up to KRW 1,500 worth of its shares pursuant to a contract with SHINYOUNG SECURITIES CO.,LTD. The purpose of the share repurchase is stock price stability and enhance in shareholder value. The repurchase program will expire on January 9, 2026. As of July 8, 2025, the company had 184,000 shares within scope available for dividend and had 262,054 shares in treasury through other repurchase. 공고 • Mar 14
Cellromax Science Co., Ltd., Annual General Meeting, Mar 28, 2025 Cellromax Science Co., Ltd., Annual General Meeting, Mar 28, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 357, guseong-ro, giheung-gu, gyeonggi-do, yongin South Korea